Literature DB >> 24870877

Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM).

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24870877

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  5 in total

Review 1.  Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Authors:  Solomon A Graf; Ajay K Gopal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 2.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

3.  Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

Authors:  Paolo Anderlini; Rima M Saliba; Celina Ledesma; Tamera Plair; Amin M Alousi; Chitra M Hosing; Issa F Khouri; Yago Nieto; Uday R Popat; Elizabeth J Shpall; Michelle A Fanale; Frederick B Hagemeister; Yasuhiro Oki; Saatva Neelapu; Jorge E Romaguera; Anas Younes; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-06       Impact factor: 5.742

4.  Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Ni-Chun Tsai; Sandra H Thomas; Tanya Siddiqi; Leslie Popplewell; Len Farol; Auayporn Nademanee; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-05       Impact factor: 5.742

Review 5.  Relapsed Hodgkin lymphoma: management strategies.

Authors:  Francesca Montanari; Catherine Diefenbach
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.